Relaxis
San Clemente · Founded 2009
About Relaxis
Relaxis develops medical device treatments for patients with restless legs syndrome. It improves the quality of sleep in patients with primary RLS through the use of vibratory counterstimulation. The company uses vibration to overwhelm the unpleasant RLS sensations by stimulating the nerves in the legs with real sensory signals. It has the “First in Class” - and only - device that is “indicated to improve the quality of sleep in patients with primary Restless Legs Syndrome (RLS) through the use of vibratory counterstimulation” as stated by the U.S. Food and Drug Administration. “First In Class” means it’s the very first medical device (vs. drug treatment) to improve the quality of sleep for sufferers of RLS. Sensory Medical was formed in 2009 after is CEO, Fred Burbank, M.D., began to experience symptoms of RLS. Dr. Burbank found relief from his RLS symptoms by getting out of bed, standing, and walking. Although his symptoms were gone, the physical act of standing or walking left him wide awake. Dr. Burbank postulated that a device providing counterstimulation, while in bed, would relieve his symptom and allow him to quickly return to sleep. We developed a series of test devices that allowed him to remain in bed while relieving his symptoms. This initial success with Dr. Burbank led to the development of the Symphony™ pad and completion of two clinical studies with 158 patients and resulted in FDA clearance to market the Relaxis™ Pad.
Company Facts
- Founded: 2009
- Legal name: Sensory NeuroStimulation, Inc.
- Operating status: Operating
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $10.5M
- Funding stage: Late Stage Venture
- Last round: Debt Financing (Jan 2015)
- Website: myrelaxis.com
- Phone: (949)492-0550
Social Profiles
Canonical: https://fsome.com/organization/relaxis-8247722 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.